Dendritic Cell Vaccine
Alzheimer's Disease
Key Facts
About MegaNano BioTech
MegaNano BioTech is a private, preclinical-stage biotech developing a versatile dendritic cell vaccine platform and related therapeutic products. The company's lead programs target Alzheimer's and Parkinson's diseases, with exploratory work in lung cancer and malaria. It is currently seeking $5-10 million in investment to advance its second Alzheimer's vaccine candidate through IND-enabling studies and Phase I clinical trials, while also preparing to commercialize a nutraceutical nasal spray.
View full company profileAbout MegaNano BioTech
MegaNano BioTech is a private, preclinical-stage biotech developing a versatile dendritic cell vaccine platform and related therapeutic products. The company's lead programs target Alzheimer's and Parkinson's diseases, with exploratory work in lung cancer and malaria. It is currently seeking $5-10 million in investment to advance its second Alzheimer's vaccine candidate through IND-enabling studies and Phase I clinical trials, while also preparing to commercialize a nutraceutical nasal spray.
View full company profileAbout MegaNano BioTech
MegaNano BioTech is a private, preclinical-stage biotech developing a versatile dendritic cell vaccine platform and related therapeutic products. The company's lead programs target Alzheimer's and Parkinson's diseases, with exploratory work in lung cancer and malaria. It is currently seeking $5-10 million in investment to advance its second Alzheimer's vaccine candidate through IND-enabling studies and Phase I clinical trials, while also preparing to commercialize a nutraceutical nasal spray.
View full company profileAbout MegaNano BioTech
MegaNano BioTech is a private, preclinical-stage biotech developing a versatile dendritic cell vaccine platform and related therapeutic products. The company's lead programs target Alzheimer's and Parkinson's diseases, with exploratory work in lung cancer and malaria. It is currently seeking $5-10 million in investment to advance its second Alzheimer's vaccine candidate through IND-enabling studies and Phase I clinical trials, while also preparing to commercialize a nutraceutical nasal spray.
View full company profileAbout Mill Creek Life Sciences
Mill Creek Life Sciences is a private, commercial-stage company providing essential raw materials for the cell therapy industry. Its primary business is the manufacturing and sale of cGMP-grade human platelet lysates (PLTMax®, PLTGold®), which are used as growth media supplements in over 50 clinical trials globally. The company leverages its deep clinical experience and a licensed dendritic cell vaccine technology to support partners in developing advanced cellular therapies. With a foundation in Mayo Clinic research, MCLS operates as a key enabler in the translational medicine ecosystem.
View full company profileOther Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |